The adult epilepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)…
Read More
Agentic Workflows to Automate Your Data Science Pipeline
The modern data science landscape is undergoing a significant transformation, driven by the imperative to increase efficiency and strategic impact.…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
Agentic Workflows to Automate Your Data Science Pipeline
The modern data science landscape is increasingly characterized by complexity and scale, yet a significant portion of a data scientist’s…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read More
Biopharma M&A Surges as Billion-Dollar Deals Fuel Pipeline Replenishment Amidst Patent Cliff Pressures
The biopharmaceutical industry is experiencing a significant resurgence in merger and acquisition (M&A) activity, driven by a wave of high-value…
Read More
Europe Must Rethink Funding and De-Risk Assets to Secure its Rare Disease Research Pipeline
The 13th European Conference on Rare Diseases and Orphan Products, held in Prague, Czech Republic, from June 3-4, 2026, served…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read MoreYOU MAY HAVE MISSED
